ReGenTree, LLC
Quick facts
Phase 3 pipeline
- RGN-259 · Ophthalmology
RGN-259 is a stem cell therapy that aims to promote retinal regeneration.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: